^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    PF-07284892 (PTPN11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

    Published date:
    08/04/2023
    Excerpt:
    A patient with KRAS G12D-mutant low-grade serous ovarian cancer underwent surgical resection and adjuvant anastrozole. For recurrent/metastatic disease...The patient continued PF-07284892 (dose decreased like the prior patients), and binimetinib was added at the approved dose. A PR (−34%) was achieved after 6 weeks of combination therapy...
    DOI:
    https://doi.org/10.1158/2159-8290.CD-23-0361